Rate My Professor Shahram Kordasti

Shahram Kordasti is Professor of Systems Cancer Immunology in the Faculty of Life Sciences & Medicine at King’s College London, serving as Research Lead for the School of Cancer & Pharmaceutical Sciences since 2024. He obtained an MSc in Medical Immunology and a PhD in Cancer Immunology from King’s College London, alongside clinical training in Internal Medicine and Haematology. His academic career progressed from Senior Lecturer in 2018, to Reader in Applied Cancer Immunopathology in 2022, and to Professor of Systems Cancer Immunology in 2025. As Group Leader of the Systems Cancer Immunology group, he concurrently practices as a Senior Clinician and Haemato-Oncologist at Guy’s and St Thomas’ NHS Foundation Trust since April 2018.

Kordasti’s research centers on the role of the immune system in bone marrow failure syndromes and myeloid malignancies, with a focus on the plasticity of CD4+ T cells—including regulatory T cells (Tregs) and Th17 cells—their interactions with inflammatory microenvironments, and immune dysregulation driving disease progression from MDS to acute leukaemia. He established the key role of Tregs in myelodysplastic syndromes (MDS) and aplastic anaemia (AA), shaping insights into treatment responses and advancing translational studies, including the first-in-human Phase I trial of autologous regulatory T cells for immune aplastic anaemia (Matto et al., Haematologica, 2026). Additional key publications include 'Prognostic value of flow cytometry in myelodysplastic neoplasms: Composition of a FCM-prognostic score (FCM-PS) for overall survival' (Santaolalla et al., HemaSphere, 2026), 'Characterization and Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes' (Kordasti et al., Journal of Clinical Oncology, 2025), and a chapter on 'Cancer immunotherapy' in Hoffbrand’s Postgraduate Haematology (O'Brien-Gore et al., 2025). Employing multidimensional cytometry (CyTOF), computational biology, and multiomics integration, his work identifies immune signatures for predicting progression and therapy outcomes, alongside exploring cell therapy strategies like Treg expansion. With 3,880 citations, he chairs the European Haematology Association Specialised Working Group on MDS, leads the i4MDS international consortium for standardizing immune monitoring, serves as Editor for Frontiers in Immunology since 2018, and delivered his inaugural lecture 'From T-rex to Tregs: An “Accidental” Professor’s Deliberate Path' in February 2026.